| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 12 | 2021 | 340 | 1.050 |
Why?
|
| Matched-Pair Analysis | 2 | 2014 | 8 | 0.870 |
Why?
|
| Drug Delivery Systems | 8 | 2021 | 216 | 0.820 |
Why?
|
| Models, Statistical | 2 | 2014 | 122 | 0.800 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 205 | 0.780 |
Why?
|
| ELAV-Like Protein 1 | 5 | 2021 | 30 | 0.740 |
Why?
|
| Peripheral Arterial Disease | 3 | 2017 | 119 | 0.670 |
Why?
|
| Quality of Life | 5 | 2022 | 467 | 0.570 |
Why?
|
| Humans | 49 | 2025 | 27136 | 0.500 |
Why?
|
| Computer Simulation | 2 | 2014 | 221 | 0.500 |
Why?
|
| Motor Disorders | 1 | 2015 | 9 | 0.480 |
Why?
|
| Knowledge | 1 | 2015 | 14 | 0.480 |
Why?
|
| Mental Health | 1 | 2015 | 97 | 0.470 |
Why?
|
| Health Status | 1 | 2015 | 145 | 0.470 |
Why?
|
| Physical Therapy Modalities | 1 | 2015 | 44 | 0.460 |
Why?
|
| Cognition Disorders | 1 | 2015 | 181 | 0.440 |
Why?
|
| Confidence Intervals | 1 | 2013 | 66 | 0.410 |
Why?
|
| Cognition | 1 | 2015 | 298 | 0.410 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 659 | 0.390 |
Why?
|
| RNA, Small Interfering | 6 | 2021 | 195 | 0.390 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 931 | 0.380 |
Why?
|
| Exosomes | 3 | 2018 | 92 | 0.380 |
Why?
|
| Exercise | 1 | 2015 | 469 | 0.370 |
Why?
|
| Transcriptome | 2 | 2025 | 205 | 0.360 |
Why?
|
| Dental Cements | 2 | 2021 | 16 | 0.350 |
Why?
|
| Nanoparticles | 4 | 2017 | 276 | 0.350 |
Why?
|
| Interleukins | 3 | 2016 | 111 | 0.350 |
Why?
|
| Cell Line, Tumor | 13 | 2020 | 1269 | 0.350 |
Why?
|
| Female | 23 | 2025 | 14650 | 0.350 |
Why?
|
| Streptococcus mutans | 2 | 2021 | 38 | 0.340 |
Why?
|
| International Classification of Diseases | 2 | 2020 | 32 | 0.340 |
Why?
|
| Apoptosis | 6 | 2020 | 740 | 0.340 |
Why?
|
| Breast Neoplasms | 4 | 2016 | 448 | 0.320 |
Why?
|
| Heart Failure | 2 | 2022 | 234 | 0.310 |
Why?
|
| Biomarkers | 7 | 2018 | 738 | 0.310 |
Why?
|
| Cell Movement | 5 | 2017 | 353 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2017 | 103 | 0.300 |
Why?
|
| Exercise Tolerance | 3 | 2022 | 82 | 0.300 |
Why?
|
| Autoantibodies | 2 | 2025 | 472 | 0.300 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 377 | 0.280 |
Why?
|
| Folate Receptor 1 | 2 | 2017 | 10 | 0.280 |
Why?
|
| Walking | 3 | 2017 | 130 | 0.270 |
Why?
|
| Colonoscopy | 2 | 2017 | 58 | 0.260 |
Why?
|
| Smoking | 3 | 2020 | 465 | 0.260 |
Why?
|
| Doxorubicin | 2 | 2016 | 74 | 0.260 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2017 | 31 | 0.250 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2017 | 42 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 446 | 0.250 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2024 | 60 | 0.240 |
Why?
|
| Cardiac Myosins | 1 | 2025 | 17 | 0.240 |
Why?
|
| Myocarditis | 1 | 2025 | 21 | 0.240 |
Why?
|
| Middle Aged | 11 | 2025 | 6906 | 0.240 |
Why?
|
| Primary Health Care | 3 | 2022 | 151 | 0.240 |
Why?
|
| Heart Ventricles | 1 | 2025 | 133 | 0.230 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 567 | 0.220 |
Why?
|
| Myocardium | 1 | 2025 | 179 | 0.220 |
Why?
|
| MicroRNAs | 2 | 2018 | 281 | 0.220 |
Why?
|
| Algorithms | 3 | 2021 | 422 | 0.210 |
Why?
|
| Oklahoma | 5 | 2020 | 978 | 0.210 |
Why?
|
| Odds Ratio | 2 | 2014 | 230 | 0.210 |
Why?
|
| Oxidative Stress | 2 | 2017 | 635 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2020 | 99 | 0.200 |
Why?
|
| Head and Neck Neoplasms | 1 | 2024 | 84 | 0.200 |
Why?
|
| Reproducibility of Results | 6 | 2020 | 751 | 0.200 |
Why?
|
| Streptococcus agalactiae | 1 | 2022 | 11 | 0.200 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2022 | 14 | 0.200 |
Why?
|
| Wheelchairs | 1 | 2021 | 5 | 0.190 |
Why?
|
| Specimen Handling | 1 | 2022 | 30 | 0.190 |
Why?
|
| Male | 13 | 2025 | 13034 | 0.190 |
Why?
|
| Pandemics | 2 | 2020 | 176 | 0.190 |
Why?
|
| Disabled Persons | 1 | 2021 | 18 | 0.190 |
Why?
|
| Streptococcal Infections | 1 | 2022 | 34 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 45 | 0.190 |
Why?
|
| Elastin | 1 | 2021 | 20 | 0.190 |
Why?
|
| Cisplatin | 2 | 2024 | 175 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2022 | 39 | 0.190 |
Why?
|
| Animals | 12 | 2025 | 10085 | 0.180 |
Why?
|
| Aortic Valve | 1 | 2021 | 90 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2016 | 153 | 0.180 |
Why?
|
| Exercise Test | 3 | 2017 | 248 | 0.180 |
Why?
|
| Cell Proliferation | 4 | 2017 | 775 | 0.180 |
Why?
|
| Mebendazole | 1 | 2020 | 10 | 0.180 |
Why?
|
| Mass Screening | 1 | 2022 | 148 | 0.180 |
Why?
|
| Neurosurgeons | 1 | 2020 | 22 | 0.180 |
Why?
|
| Models, Organizational | 1 | 2020 | 18 | 0.180 |
Why?
|
| Exercise Therapy | 2 | 2022 | 80 | 0.180 |
Why?
|
| Preventive Health Services | 1 | 2020 | 15 | 0.180 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 64 | 0.180 |
Why?
|
| Rural Health Services | 1 | 2020 | 22 | 0.180 |
Why?
|
| Health Resources | 2 | 2017 | 18 | 0.170 |
Why?
|
| Blood Pressure Determination | 1 | 2020 | 26 | 0.170 |
Why?
|
| Aged | 7 | 2020 | 5228 | 0.170 |
Why?
|
| DEAD Box Protein 58 | 2 | 2017 | 18 | 0.170 |
Why?
|
| Ketorolac | 1 | 2020 | 9 | 0.170 |
Why?
|
| Risk Assessment | 2 | 2020 | 595 | 0.170 |
Why?
|
| Ibuprofen | 1 | 2020 | 17 | 0.170 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2020 | 13 | 0.170 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 34 | 0.170 |
Why?
|
| Papillary Muscles | 1 | 2020 | 14 | 0.170 |
Why?
|
| Chordae Tendineae | 1 | 2020 | 9 | 0.170 |
Why?
|
| Endothelial Cells | 3 | 2017 | 331 | 0.170 |
Why?
|
| Tricuspid Valve | 1 | 2020 | 24 | 0.170 |
Why?
|
| Aza Compounds | 1 | 2020 | 11 | 0.170 |
Why?
|
| Endocarditis | 1 | 2020 | 16 | 0.170 |
Why?
|
| Adult | 10 | 2025 | 7499 | 0.170 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 51 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.170 |
Why?
|
| Medical Records | 1 | 2019 | 49 | 0.170 |
Why?
|
| Workload | 2 | 2020 | 38 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2020 | 60 | 0.170 |
Why?
|
| Mitral Valve | 1 | 2020 | 58 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2018 | 189 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 73 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 60 | 0.160 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 43 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 47 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 51 | 0.160 |
Why?
|
| Aspirin | 1 | 2020 | 122 | 0.160 |
Why?
|
| Chromans | 1 | 2020 | 59 | 0.160 |
Why?
|
| Thiones | 1 | 2020 | 55 | 0.160 |
Why?
|
| Neurosurgery | 1 | 2020 | 75 | 0.160 |
Why?
|
| Cyclonic Storms | 1 | 2018 | 5 | 0.160 |
Why?
|
| Interleukin-2 | 1 | 2018 | 33 | 0.160 |
Why?
|
| Aptamers, Nucleotide | 2 | 2015 | 13 | 0.150 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 8 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2019 | 251 | 0.150 |
Why?
|
| Hospitalization | 1 | 2020 | 189 | 0.150 |
Why?
|
| Urinalysis | 1 | 2018 | 11 | 0.150 |
Why?
|
| E-Selectin | 2 | 2015 | 27 | 0.150 |
Why?
|
| Survivors | 1 | 2018 | 36 | 0.150 |
Why?
|
| Antioxidants | 2 | 2017 | 220 | 0.150 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 216 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 123 | 0.150 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2017 | 10 | 0.150 |
Why?
|
| Comorbidity | 2 | 2015 | 252 | 0.150 |
Why?
|
| Dendrimers | 1 | 2017 | 15 | 0.150 |
Why?
|
| Functional Food | 1 | 2017 | 5 | 0.140 |
Why?
|
| Arthralgia | 1 | 2017 | 7 | 0.140 |
Why?
|
| Fragaria | 1 | 2017 | 4 | 0.140 |
Why?
|
| Theranostic Nanomedicine | 1 | 2018 | 22 | 0.140 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2018 | 68 | 0.140 |
Why?
|
| Time Factors | 3 | 2017 | 1571 | 0.140 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 446 | 0.140 |
Why?
|
| Fruit | 1 | 2017 | 38 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 52 | 0.140 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 24 | 0.140 |
Why?
|
| Oncogenes | 1 | 2017 | 34 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 177 | 0.140 |
Why?
|
| HMGA1a Protein | 1 | 2016 | 4 | 0.140 |
Why?
|
| Croup | 1 | 2016 | 1 | 0.140 |
Why?
|
| Tracheomalacia | 1 | 2016 | 1 | 0.140 |
Why?
|
| Bronchomalacia | 1 | 2016 | 1 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2018 | 110 | 0.140 |
Why?
|
| Internship and Residency | 2 | 2020 | 228 | 0.140 |
Why?
|
| United States | 3 | 2020 | 2061 | 0.140 |
Why?
|
| Laryngostenosis | 1 | 2016 | 2 | 0.140 |
Why?
|
| Gastroenterologists | 1 | 2016 | 6 | 0.130 |
Why?
|
| Equipment and Supplies | 1 | 2016 | 10 | 0.130 |
Why?
|
| Heart Rate | 1 | 2018 | 375 | 0.130 |
Why?
|
| Cost Savings | 1 | 2016 | 19 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2017 | 184 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 312 | 0.130 |
Why?
|
| Depression | 1 | 2018 | 212 | 0.130 |
Why?
|
| RNAi Therapeutics | 1 | 2016 | 13 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 187 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 353 | 0.130 |
Why?
|
| Bronchoscopy | 1 | 2016 | 34 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 270 | 0.130 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2016 | 16 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 930 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 54 | 0.130 |
Why?
|
| Reference Standards | 3 | 2020 | 54 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 36 | 0.130 |
Why?
|
| Nanotubes | 1 | 2015 | 15 | 0.130 |
Why?
|
| Mucin-1 | 1 | 2016 | 36 | 0.130 |
Why?
|
| Mobility Limitation | 1 | 2015 | 14 | 0.130 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 84 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2015 | 27 | 0.120 |
Why?
|
| Interferon Type I | 1 | 2016 | 55 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2019 | 467 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2016 | 103 | 0.120 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2015 | 3 | 0.120 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2015 | 6 | 0.120 |
Why?
|
| Coitus | 1 | 2015 | 14 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 95 | 0.120 |
Why?
|
| Chemokine CXCL12 | 1 | 2015 | 9 | 0.120 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 128 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2015 | 27 | 0.120 |
Why?
|
| Cell Death | 3 | 2024 | 111 | 0.120 |
Why?
|
| Physicians | 1 | 2015 | 80 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2016 | 1379 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 101 | 0.120 |
Why?
|
| Glottis | 1 | 2014 | 4 | 0.120 |
Why?
|
| Laryngeal Neoplasms | 1 | 2014 | 8 | 0.120 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 39 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 26 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 150 | 0.120 |
Why?
|
| Gold | 1 | 2015 | 129 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 127 | 0.110 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 35 | 0.110 |
Why?
|
| Proton Therapy | 1 | 2014 | 28 | 0.110 |
Why?
|
| Smoke | 1 | 2014 | 36 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 251 | 0.110 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 102 | 0.110 |
Why?
|
| Tobacco | 1 | 2014 | 86 | 0.110 |
Why?
|
| Learning | 1 | 2015 | 95 | 0.110 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 64 | 0.110 |
Why?
|
| Risk Factors | 2 | 2016 | 2035 | 0.110 |
Why?
|
| Neoplasms | 1 | 2022 | 768 | 0.110 |
Why?
|
| Immunity, Innate | 1 | 2014 | 212 | 0.100 |
Why?
|
| Obesity | 1 | 2017 | 654 | 0.090 |
Why?
|
| Research Design | 1 | 2013 | 174 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2022 | 111 | 0.090 |
Why?
|
| Biomechanical Phenomena | 2 | 2021 | 162 | 0.090 |
Why?
|
| Swine | 2 | 2021 | 221 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2020 | 1219 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 516 | 0.080 |
Why?
|
| Biofilms | 2 | 2021 | 119 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2020 | 132 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 988 | 0.080 |
Why?
|
| Child | 1 | 2015 | 2163 | 0.080 |
Why?
|
| Drug Synergism | 2 | 2020 | 100 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2020 | 163 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2020 | 2456 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2020 | 313 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 472 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2019 | 155 | 0.070 |
Why?
|
| Receptors, Transferrin | 2 | 2017 | 17 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 180 | 0.070 |
Why?
|
| Caspase 9 | 2 | 2016 | 16 | 0.070 |
Why?
|
| Drug Liberation | 2 | 2016 | 24 | 0.070 |
Why?
|
| Doxycycline | 2 | 2016 | 19 | 0.060 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 153 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 310 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2016 | 265 | 0.060 |
Why?
|
| Transfection | 2 | 2017 | 314 | 0.060 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 280 | 0.060 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2025 | 24 | 0.060 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2025 | 19 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2019 | 648 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2025 | 72 | 0.060 |
Why?
|
| Kinetics | 2 | 2016 | 538 | 0.060 |
Why?
|
| Cell Survival | 2 | 2017 | 395 | 0.060 |
Why?
|
| DNA Damage | 2 | 2016 | 149 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 76 | 0.060 |
Why?
|
| Gene Expression | 2 | 2017 | 408 | 0.060 |
Why?
|
| Fibrosis | 1 | 2025 | 121 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 462 | 0.060 |
Why?
|
| Age Factors | 2 | 2016 | 724 | 0.060 |
Why?
|
| Epitopes | 1 | 2025 | 181 | 0.060 |
Why?
|
| Mitochondria | 2 | 2017 | 342 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 498 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 1943 | 0.050 |
Why?
|
| Lung | 2 | 2016 | 363 | 0.050 |
Why?
|
| Perineum | 1 | 2022 | 14 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 11 | 0.050 |
Why?
|
| Mice | 3 | 2017 | 4474 | 0.050 |
Why?
|
| Rectum | 1 | 2022 | 50 | 0.050 |
Why?
|
| Vagina | 1 | 2022 | 42 | 0.050 |
Why?
|
| Weight-Bearing | 1 | 2021 | 39 | 0.050 |
Why?
|
| Stress, Mechanical | 1 | 2021 | 104 | 0.050 |
Why?
|
| Smartphone | 1 | 2021 | 58 | 0.050 |
Why?
|
| Nanomedicine | 1 | 2021 | 62 | 0.050 |
Why?
|
| Fenbendazole | 1 | 2020 | 8 | 0.050 |
Why?
|
| Quinuclidines | 1 | 2020 | 10 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2020 | 11 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 2631 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 14 | 0.040 |
Why?
|
| Health Information Exchange | 1 | 2020 | 6 | 0.040 |
Why?
|
| Collagen | 1 | 2021 | 147 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 102 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 148 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 101 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 58 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 49 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 27 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2020 | 15 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2019 | 9 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 95 | 0.040 |
Why?
|
| Health Personnel | 1 | 2020 | 91 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 90 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 21 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2020 | 113 | 0.040 |
Why?
|
| Prostate | 1 | 2019 | 51 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 190 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2019 | 83 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 225 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 478 | 0.040 |
Why?
|
| Curriculum | 1 | 2020 | 271 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 16 | 0.040 |
Why?
|
| Pregnancy | 1 | 2022 | 1150 | 0.040 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2017 | 6 | 0.040 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 5 | 0.040 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2017 | 4 | 0.040 |
Why?
|
| Freeze Drying | 1 | 2017 | 10 | 0.040 |
Why?
|
| Inhalation Exposure | 1 | 2017 | 15 | 0.040 |
Why?
|
| Chitosan | 1 | 2017 | 31 | 0.040 |
Why?
|
| Caspases | 1 | 2017 | 43 | 0.040 |
Why?
|
| Mortality | 1 | 2017 | 43 | 0.040 |
Why?
|
| G1 Phase | 1 | 2017 | 15 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2017 | 32 | 0.040 |
Why?
|
| Knee Joint | 1 | 2017 | 42 | 0.040 |
Why?
|
| Static Electricity | 1 | 2017 | 34 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2017 | 30 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 458 | 0.040 |
Why?
|
| Hydroxyl Radical | 1 | 2017 | 7 | 0.040 |
Why?
|
| Fitness Trackers | 1 | 2017 | 10 | 0.030 |
Why?
|
| Actigraphy | 1 | 2017 | 22 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 64 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 375 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2017 | 132 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2017 | 34 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2016 | 15 | 0.030 |
Why?
|
| Community Health Services | 1 | 2017 | 32 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 440 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 290 | 0.030 |
Why?
|
| Colorectal Surgery | 1 | 2016 | 7 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 763 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 131 | 0.030 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 11 | 0.030 |
Why?
|
| Dogs | 1 | 2017 | 505 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2017 | 115 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 93 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 39 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 187 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 2016 | 19 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 26 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 405 | 0.030 |
Why?
|
| Folic Acid | 1 | 2016 | 32 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 60 | 0.030 |
Why?
|
| Premature Birth | 1 | 2016 | 49 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 24 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 819 | 0.030 |
Why?
|
| Transferrin | 1 | 2015 | 9 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 489 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2016 | 153 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 397 | 0.030 |
Why?
|
| B-Cell Activating Factor | 1 | 2016 | 31 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2016 | 94 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2016 | 50 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 389 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2016 | 151 | 0.030 |
Why?
|
| Recurrence | 1 | 2016 | 316 | 0.030 |
Why?
|
| Complement C5a | 1 | 2015 | 5 | 0.030 |
Why?
|
| Complement C3a | 1 | 2015 | 6 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 20 | 0.030 |
Why?
|
| Mice, Inbred ICR | 1 | 2015 | 26 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 25 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 65 | 0.030 |
Why?
|
| Endocytosis | 1 | 2015 | 81 | 0.030 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2015 | 5 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 111 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 68 | 0.030 |
Why?
|
| Life Style | 1 | 2015 | 83 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 26 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 278 | 0.030 |
Why?
|
| Benzylamines | 1 | 2015 | 19 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 33 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 23 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 299 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 262 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2015 | 15 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 411 | 0.030 |
Why?
|
| Cholesterol | 1 | 2016 | 182 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 82 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 129 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2015 | 25 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 43 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2015 | 28 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 218 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2015 | 133 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 253 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2014 | 26 | 0.030 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 242 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2014 | 22 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 325 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 116 | 0.030 |
Why?
|
| Interferon-beta | 1 | 2014 | 40 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 81 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2014 | 49 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 264 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 977 | 0.030 |
Why?
|
| Radiometry | 1 | 2014 | 44 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2015 | 116 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2016 | 864 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 568 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 707 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 589 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 506 | 0.030 |
Why?
|
| Kidney | 1 | 2015 | 276 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 243 | 0.030 |
Why?
|
| Inflammation | 1 | 2017 | 608 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 967 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 509 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 1103 | 0.030 |
Why?
|
| Cytokines | 1 | 2015 | 440 | 0.030 |
Why?
|
| Adolescent | 1 | 2020 | 2995 | 0.030 |
Why?
|
| Liver | 1 | 2015 | 424 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 2285 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 1496 | 0.020 |
Why?
|